Matching articles for "zostavax"
Issue 1661 · October 17, 2022
Adult Immunization

The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these…

Med Lett Drugs Ther. 2022 Oct 17; 64(1661):161-8
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
Issue 1546 · May 7, 2018
Adult Immunization

The US Advisory Committee on Immunization Practices (ACIP) recommends routine use of the following vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with…

Med Lett Drugs Ther. 2018 May 7; 60(1546):73-82
The US Advisory Committee on Immunization Practices (ACIP) recommends routine use of the following vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with acellular pertussis (Tdap), measles/mumps/rubella (MMR), varicella (VAR), herpes zoster (RZV; ZVL), human papillomavirus (HPV), and pneumococcal conjugate (PCV13) and polysaccharide (PPSV23) vaccines. For adults with certain medical conditions or occupational, behavioral, or other risk factors, hepatitis A (HepA), hepatitis B (HepB), meningococcal (MenACWY; MenB), and Haemophilus influenzae type b (Hib) vaccines are also recommended. Recommendations for vaccination against seasonal influenza and vaccination of travelers are reviewed separately.
Issue 1546 · May 7, 2018
Expanded Table: Some Vaccines Recommended for Use in Adults (online only)

View the Expanded Table: Some Vaccines Recommended for Use in Adults

Med Lett Drugs Ther. 2018 May 7; 60(1546):e82-5
View the Expanded Table: Some Vaccines Recommended for Use in Adults
Issue 1535 · December 4, 2017
Shingrix - An Adjuvanted, Recombinant Herpes Zoster Vaccine

The FDA has approved an adjuvanted, recombinant varicella zoster virus (VZV) vaccine ( Shingrix – GSK) for prevention of herpes zoster (shingles) in adults ≥50 years old. Shingrix is the second herpes…

Med Lett Drugs Ther. 2017 Dec 4; 59(1535):195-6
The FDA has approved an adjuvanted, recombinant varicella zoster virus (VZV) vaccine ( Shingrix – GSK) for prevention of herpes zoster (shingles) in adults ≥50 years old. Shingrix is the second herpes zoster vaccine to be approved in the US; Zostavax , a live-attenuated VZV vaccine approved for the same indication, has been available since 2006.
Issue 112 · December 1, 2011
Adult Immunizations

Vaccines recommended for routine use in US adults are reviewed here. Vaccines for travel have been reviewed separately.

Treat Guidel Med Lett. 2011 Dec; 9(112):75-82
Vaccines recommended for routine use in US adults are reviewed here. Vaccines for travel have been reviewed separately.
Issue 1339 · May 31, 2010 Free
In Brief: Herpes Zoster Vaccine (Zostavax) Revisited

The 2006 Medical Letter article on the then-new varicella-zoster vaccine concluded that Zostavax appears to be safe and effective in protecting patients ≥60 years old against herpes zoster and postherpetic…

Med Lett Drugs Ther. 2010 May 31; 52(1339):41
The 2006 Medical Letter article on the then-new varicella-zoster vaccine concluded that Zostavax appears to be safe and effective in protecting patients ≥60 years old against herpes zoster and postherpetic neuralgia, especially in reducing the severity and duration of the disease. 1 Some new information has recently become available. CLINICAL STUDIES — A Veterans Administration randomized, double-blind trial enrolled more than 38,000 patients ≥60 years old and followed them for a mean of 3.4 years after administration of Zostavax or placebo. Since the efficacy of the vaccine had been demonstrated previously (51% in preventing zoster and 67% in preventing postherpetic neuralgia), the objective of this study was to examine its safety. Transient varicella-like rash occurred at the inoculation site in 0.11% of vaccine recipients and in 0.04% of patients who received a placebo injection. Erythema, swelling, pain and tenderness at the injection site were more frequent and more severe with the vaccine than with placebo. There were no other significant differences. Serious adverse events occurred in 1.4% of patients in each group. 2 USE — Despite its efficacy and the frequency and morbidity of herpes zoster, this vaccine is hardly used. One study in 2007 found that only 2% of patients ≥60 years old had received it. 3 A 2008 survey found that 7% of potential recipients had been vaccinated. 4 A study of the reasons for such sparse usage concluded that the expense ($194 wholesale), the need for a freezer to store the vaccine (a vaccine that can be kept in a refrigerator is available in Europe), and reimbursement through Medicare Part D, which generally provides pharmacy benefits, rather than Part B, which physicians are more familiar with, were contributing factors. 5 CONCLUSION — The efficacy of the herpes zoster vaccine (Zostavax) was well established before the FDA approved it in 2006. Several years’ use has now provided more data supporting the safety of the vaccine. It deserves wider use. 1. Herpes zoster vaccine (Zostavax). Med Lett Drugs Ther 2006; 48:73. 2. MS Simberkoff et al. Safety of herpes zoster vaccine in the shingles prevention study. Ann Intern Med 2010; 152:545. 3. PJ Lu et al. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine 2009; 27:882. 4. JS Schiller and GL Euler. Vaccination coverage estimates from the National Health Interview Survey: United States, 2008. Atlanta: Centers for Disease Control and Prevention 2009. Accessed at www.cdc.gov/nchs/data/hestat/vaccine_coverage/vaccine_coverage.pdf on 12 May 2010. 5. LP Hurley et al. Barriers to the use of herpes zoster vaccine. Ann Intern Med 2010; 152:555. Download: U.S. English
Issue 80 · April 1, 2009
Adult Immunization

Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed…

Treat Guidel Med Lett. 2009 Apr; 7(80):27-36
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed here. Vaccines for travel are reviewed separately.
Issue 1243 · September 11, 2006
Herpes Zoster Vaccine (Zostavax)

A live attenuated varicella-zoster vaccine ( Zostavax - Merck) has been approved by the FDA for prevention of herpes zoster (HZ; zoster; shingles) in persons ≥60 years old. Each dose of Zostavax contains…

Med Lett Drugs Ther. 2006 Sep 11; 48(1243):73-4
A live attenuated varicella-zoster vaccine ( Zostavax - Merck) has been approved by the FDA for prevention of herpes zoster (HZ; zoster; shingles) in persons ≥60 years old. Each dose of Zostavax contains about 14 times as much varicella-zoster virus (VZV) as Varivax , which has been used in the US since 1995 to vaccinate against varicella (chicken pox).
Issue 47 · July 1, 2006
Adult Immunization

Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed…

Treat Guidel Med Lett. 2006 Jul; 4(47):47-54
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed here. Immunizations for travel were reviewed in a recent issue.